Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations

Table 3 Predictors of Treatment Adherence (MPR and 1-year PDC ≥80%), REACH-OUT (2010–2013)

	MPR		PDC
VARIABLE	β (95% CI)	P Value	OR (95% CI)	P Value
Treatment cohort:
OAT	Reference		Reference
PP-N	0.36 (0.31–0.42)	<0.001	10.27 (5.55–19.00)	<0.001
PP-C	0.39 (0.34–0.44)	<0.001	16.47 (9.12–29.75)	<0.001
Assertive community treatment	–	–	3.00 (1.37–6.59)	0.006
Age (10-year increase)	0.03 (0.01–0.05)	0.008	1.29 (1.03–1.62)	0.028
Arrested in last month	0.13 (0.01–0.25)	0.029	4.17 (1.14–15.32)	0.031
Private residence	–	–	1.89 (1.15–3.13)	0.012
Black/African American	–	–	0.40 (0.24–0.67)	0.001
Heart disease	–	–	3.38 (1.36–8.72)	0.010
Substance abuse	–	–	0.44 (0.28–0.70)	0.001
Duration of schizophrenia (10-year increase)	−0.03 (−0.05 to −0.01)	0.007	0.81 (0.64–1.02)	0.068

Notes: Adjusted logistic regression models, including all variables listed, plus the following additional model-specific covariates. MPR: Drug Attitude Inventory-10 score; Quality of Life social interaction domain score; hospitalizations/ED visits; insurance; gender; marital status; psychiatric comorbidities; and physical comorbidities. PDC: medication satisfaction; hospitalizations/ED visits; insurance; gender; Hispanic or other race/ethnicity; psychiatric comorbidities; physical comorbidities; alcohol abuse; and frequency of strength training
Abbreviations: CI confidence interval, ED emergency department, MPR medication possession ratio, OAT oral antipsychotic therapy, PDC proportion of days covered, PP paliperidone palmitate, PP-C continuous user of paliperidone palmitate, PP-N new user of paliperidone palmitate

ISSN: 1471-244X